Ardelyx Stock Price, News & Analysis

Ardelyx, Inc. (Nasdaq: ARDX) presented new data on tenapanor at the ERA-EDTA Virtual Congress 2021. Interim results from the OPTIMIZE study indicate that tenapanor significantly improves phosphorus control in patients with chronic kidney disease (CKD) on dialysis. Approximately 50% of previously uncontrolled patients achieved target phosphorus levels. Additionally, tenapanor demonstrated lower rates of deaths and hospitalizations versus sevelamer in the PHREEDOM study. Ardelyx continues to advance tenapanor while its NDA is under FDA review, with a PDUFA date of July 29, 2021.

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company, announced that CEO Mike Raab will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:30 p.m. ET. The live webcast can be accessed on the company's Investor website, with a replay available for 60 days. Ardelyx is focused on developing first-in-class medicines for kidney and cardiorenal diseases, including tenapanor, which is currently under FDA review for managing serum phosphorus in CKD patients. The company also received FDA approval for IBSRELA® in September 2020.

Ardelyx, Inc. (Nasdaq: ARDX) has announced its Q1 2021 financial results, highlighting a revenue of $6.6 million, primarily from a $5 million milestone from Kyowa Kirin. The company's cash position stood at $178.2 million, down from $188.6 million at year-end 2020. R&D expenses surged by 29% to $20.5 million, while G&A expenses skyrocketed by 140% to $17.1 million. Net loss for the quarter was $33.2 million, compared to $22.4 million in Q1 2020. The PDUFA date for tenapanor is extended to July 29, 2021.

Ardelyx, Inc. (Nasdaq: ARDX) announced a three-month extension of the PDUFA date for tenapanor, aimed at controlling serum phosphorus in adult CKD patients on dialysis, now set for July 29, 2021. This decision follows FDA requests for additional analyses regarding tenapanor's clinical data. CEO Mike Raab expressed disappointment but acknowledged the impact of the COVID-19 pandemic on the FDA's operations. Tenapanor's NDA is backed by extensive clinical trials involving over 1,000 patients, demonstrating its potential efficacy in managing hyperphosphatemia.

On April 12, 2021, Ardelyx (Nasdaq: ARDX) granted stock options for 125,622 shares and restricted stock units for 26,315 shares to its new Chief People Officer, Sarah O'Brien, under its Employment Commencement Incentive Plan. The option's exercise price is $7.03, equal to Ardelyx's closing stock price on that date. The awards vest over four years, contingent on continued employment. Ardelyx is advancing its product candidate, tenapanor, for FDA review, with a decision expected by April 29, 2021, indicating ongoing progress in their pipeline focused on kidney diseases.

Ardelyx, Inc. (Nasdaq: ARDX) announced that its partner Kyowa Kirin has begun four Phase 3 clinical trials in Japan for tenapanor, aimed at treating hyperphosphatemia. This milestone triggers a $5 million payment to Ardelyx. The trials include various study designs assessing tenapanor's effectiveness in patients with chronic kidney disease (CKD) on dialysis. Ardelyx is expecting a PDUFA date on April 29, 2021, for tenapanor's review by the FDA. The collaboration could yield up to $55 million in total development milestones and significant sales royalties.

Ardelyx, Inc. (Nasdaq: ARDX) announced the presentation of a poster at the ISN World Congress of Nephrology 2021, highlighting data from its NORMALIZE Phase 4 trial. This study evaluates the efficacy of tenapanor alone or with sevelamer in achieving normal serum phosphorus levels in chronic kidney disease patients on dialysis. The virtual event will occur from April 16-19, 2021. Additionally, Ardelyx is advancing tenapanor for FDA review, with a PDUFA date of April 29, 2021, and has received FDA approval for IBSRELA (tenapanor) on September 12, 2019.

Ardelyx, Inc. (Nasdaq: ARDX) announced its participation in the National Kidney Foundation 2021 Spring Clinical Meeting, taking place virtually from April 6-10, 2021. The company will present two posters focused on phosphate absorption and hyperphosphatemia management. Additionally, Ardelyx is sponsoring an educational session on hyperphosphatemia management and an exhibitor showcase. Their product candidate, tenapanor, is under review by the FDA, with a PDUFA date of April 29, 2021, aimed at controlling serum phosphorus in chronic kidney disease patients on dialysis.

Ardelyx, Inc. (Nasdaq: ARDX) appointed Muna Bhanji, R.Ph, to its board of directors on March 11, 2021, while Gordon Ringold, Ph.D., stepped down the same day. Bhanji, with over 30 years of experience in biopharmaceuticals, previously held leadership roles at Merck and focuses on drug access and affordability. Her guidance is expected to aid Ardelyx as it approaches the potential launch of tenapanor, a treatment for chronic kidney disease patients on dialysis, with FDA review ongoing ahead of a PDUFA date of April 29, 2021. Ardelyx aims to enhance patient access while continuing to advance innovative therapies.